| Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies J Kauer, S Hörner, L Osburg, S Müller, M Märklin, JS Heitmann, L Zekri, ... Journal for Immunotherapy of Cancer 8 (1), 2020 | 46 | 2020 |
| An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer L Zekri, F Vogt, L Osburg, S Müller, J Kauer, T Manz, M Pflügler, A Maurer, ... EMBO molecular medicine 13 (2), e11902, 2021 | 35 | 2021 |
| CD105 (Endoglin) as negative prognostic factor in AML J Kauer, K Schwartz, C Tandler, C Hinterleitner, M Roerden, G Jung, ... Scientific reports 9 (1), 1-11, 2019 | 29 | 2019 |
| A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL NK Mehta, M Pfluegler, K Meetze, B Li, I Sindel, F Vogt, M Marklin, ... Journal for Immunotherapy of Cancer 10 (3), 2022 | 25 | 2022 |
| Identification of CD318 (CDCP1) as novel prognostic marker in AML JS Heitmann, I Hagelstein, C Hinterleitner, M Roerden, G Jung, HR Salih, ... Annals of Hematology 99, 477-486, 2020 | 19 | 2020 |
| Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with … JS Heitmann, JS Walz, M Pflügler, J Kauer, RF Schlenk, G Jung, HR Salih BMJ open 10 (10), e039639, 2020 | 16 | 2020 |
| Fc gamma receptor expression serves as prognostic and diagnostic factor in AML JS Heitmann, I Hagelstein, C Hinterleitner, L Osburg, HR Salih, J Kauer, ... Leukemia & Lymphoma 61 (10), 2466-2474, 2020 | 8 | 2020 |
| Identification of CD105 (endoglin) as novel risk marker in CLL SM Greiner, M Märklin, S Holzmayer, K Kaban, S Meyer, C Hinterleitner, ... Annals of hematology 101 (4), 773-780, 2022 | 6 | 2022 |
| Prolonged Exposure to Oxaliplatin during HIPEC Improves Effectiveness in a Preclinical Micrometastasis Model N Seyfried, C Yurttas, M Burkard, B Oswald, A Tolios, F Herster, J Kauer, ... Cancers 14 (5), 1158, 2022 | 6 | 2022 |
| Genetic loss of LCK kinase leads to acceleration of chronic lymphocytic leukemia M Märklin, AR Fuchs, C Tandler, JS Heitmann, HR Salih, J Kauer, ... Frontiers in Immunology 11, 1995, 2020 | 6 | 2020 |
| CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation M Märklin, I Hagelstein, C Hinterleitner, HR Salih, J Kauer, JS Heitmann International Journal of Hematology 112, 57-64, 2020 | 6 | 2020 |
| Autologous stem cell collection after daratumumab, bortezomib, thalidomide, and dexamethasone versus bortezomib, cyclophosphamide, and dexamethasone in newly diagnosed multiple … S Sauer, K Kriegsmann, C Nientiedt, A Schmitt, C Müller-Tidow, MS Raab, ... Transfusion Medicine and Hemotherapy 50 (5), 371-381, 2023 | 5 | 2023 |
| Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia M Marconato, J Kauer, HR Salih, M Märklin, JS Heitmann Scientific Reports 12 (1), 15856, 2022 | 5 | 2022 |
| Genetic loss of NFAT2 (NFATc1) impairs B cell development of B1 and B2 B cells M Märklin, JS Heitmann, J Kauer, S Wirths, MR Mueller Cellular Immunology 349, 104048, 2020 | 5 | 2020 |
| Mass spectrometry for quality control of bispecific antibodies after SDS‐PAGE in‐gel digestion S Hörner, M Ghosh, J Kauer, P Spät, HG Rammensee, G Jung, M Pflügler Biotechnology and Bioengineering 118 (8), 3069-3075, 2021 | 4 | 2021 |
| BCR:: ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro J Kauer, M Märklin, M Pflügler, S Hörner, C Hinterleitner, C Tandler, ... Journal of Cancer Research and Clinical Oncology 148 (10), 2759-2771, 2022 | 3 | 2022 |
| IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases S Hörner, M Moustafa-Oglou, K Teppert, I Hagelstein, J Kauer, M Pflügler, ... Cancers 14 (16), 3941, 2022 | 3 | 2022 |
| Short-term oxaliplatin exposure according to established hyperthermic intraperitoneal chemotherapy (HIPEC) protocols lacks effectiveness in vitro and ex vivo MW Löffler, N Seyfried, M Burkard, B Oswald, A Tolios, C Yurttas, ... bioRxiv, 709055, 2019 | 3 | 2019 |
| Impact of clinical parameters and induction regimens on peripheral blood stem-cell mobilization and collection in multiple myeloma patients S Sauer, L Hieke, J Brandt, C Müller-Tidow, A Schmitt, J Kauer, ... Transfusion Medicine and Hemotherapy 50 (5), 382-395, 2023 | 2 | 2023 |
| CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies J Kauer, F Vogt, I Hagelstein, S Hörner, M Märklin, S Maurer, HR Salih, ... Cancers 13 (18), 4596, 2021 | 2 | 2021 |
Salih HRMedical Director, KKE Translational Immunology, Department of Internal Medicine, Eberhard Karls University Tübingen在 med.uni-tuebingen.de 的电子邮件经过验证
